Transitional Cell Carcinoma Clinical Trial
Official title:
Single-Arm Phase II Combination Study of Low-Dose Paclitaxel With Pembrolizumab in Platinum-Refractory Urothelial Carcinoma
This phase II trial studies how well paclitaxel and pembrolizumab works in treating patients with urothelial cancer that has not responded to previous treatment and has spread to other places in the body. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving paclitaxel together with pembrolizumab may be an effective treatment for urothelial cancer.
PRIMARY OBJECTIVES: I. To estimate the overall response rate (ORR) of pembrolizumab combined with paclitaxel. SECONDARY OBJECTIVES: I. To determine the safety and tolerability of pembrolizumab combined with paclitaxel. II. To calculate the progression-free survival (PFS) rate at 6 months. TERTIARY OBJECTIVES: I. To determine the immune effects of pembrolizumab combined with paclitaxel. II. To associate immune effects with tumor response. III. To explore changes in immune-regulatory micro ribonucleic acids (RNAs) as biomarkers of response. OUTLINE: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 and paclitaxel IV over 60 minutes on day 1 and 8. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up within 30 days and then every 3 months for 1 year. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03296306 -
Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma
|
Phase 3 | |
| Completed |
NCT00880334 -
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
|
Phase 2 | |
| Completed |
NCT00216801 -
Relationship of Ochratoxin A to Upper Urologic Cancers
|
N/A | |
| Withdrawn |
NCT04179110 -
Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor
|
Phase 2 | |
| Completed |
NCT00070070 -
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
|
Phase 1 | |
| Completed |
NCT00154687 -
Weekly TP-HDFL in the Treatment of Advanced TCC
|
Phase 2 | |
| Completed |
NCT03256877 -
Detecting Transitional Cell Carcinoma From Haematuria
|
||
| Withdrawn |
NCT04006691 -
Efficacy and Safety of UGN-101 in Recurrent Patients
|
Phase 3 | |
| Terminated |
NCT05052372 -
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
|
||
| Completed |
NCT00714025 -
A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy
|
Phase 2 | |
| Terminated |
NCT01310803 -
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
|
Phase 3 | |
| Completed |
NCT00623831 -
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
|
Phase 1 | |
| Completed |
NCT00173862 -
Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC
|
Phase 2 | |
| Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
| Terminated |
NCT01438112 -
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT00683059 -
Single Agent Abraxane as Second Line Therapy in Bladder Cancer
|
Phase 2 | |
| Recruiting |
NCT04811846 -
CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood
|
N/A | |
| Not yet recruiting |
NCT04878250 -
Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder
|
Phase 2 | |
| Completed |
NCT00633789 -
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
|
Phase 2 | |
| Completed |
NCT00612326 -
Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging
|
N/A |